Amneal Pharmaceuticals, Inc.(AMRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Amneal Pharmaceuticals, Inc. (AMRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMRX at 58.5/100 on a 32-signal composite quality model, placing it at rank #1,005 of 2,961 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (36.6) and free cash flow (39.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Amneal Pharmaceuticals, Inc. reports quarterly revenue of $796.2M, net income of $57.7M, an operating margin of 16.3%. Top institutional holders of AMRX by reported 13-F value include BlackRock, TPG GP A, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. AMRX trades on the Nasdaq exchange and files with the SEC under CIK 1723128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amneal Pharmaceuticals, Inc. directly from SEC EDGAR.